

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4962108

| | |
|---|---|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| JOHN WATKINS | 02/22/2018 |
| ALEXANDER OKSCHE | 10/20/2017 |
| KEVIN SMITH | 10/17/2017 |
| HEIKKI MANSIKKA | 11/02/2017 |
| PAUL BAILEY | 05/11/2018 |
| RECEIVING PARTY DATA | |
| Name: | EURO-CELTIQUE S.A. |
| Street Address: | 1, RUE JEAN PIRET |
| City: | LUXEMBOURG |
| State/Country: | LUXEMBOURG |
| Postal Code: | L-2350 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 14894775 |
| CORRESPONDENCE DATA | |
| Fax Number: | (202)371-2540 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | (202) 371-2600 |
| Email: | jcovert@sternekessler.com, tarjahn@sternekessler.com, dcolonna@sternekessler.com |
| Correspondent Name: | STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C |
| Address Line 1: | 1100 NEW YORK AVENUE, N.W. |
| Address Line 4: | WASHINGTON, D.C. 20005 |
| ATTORNEY DOCKET NUMBER: | 1861.4150001/JMC/THN |
| NAME OF SUBMITTER: | JOHN M. COVERT, #38,759 |
| SIGNATURE: | /John M. Covert, #38,759/ |
| DATE SIGNED: | 05/15/2018 |
| Total Attachments: 15 | |
| source=1861_4150001_Assignment#page1.tif | |

source=1861_4150001_Assignment#page2.tif
source=1861_4150001_Assignment#page3.tif
source=1861_4150001_Assignment#page4.tif
source=1861_4150001_Assignment#page5.tif
source=1861_4150001_Assignment#page6.tif
source=1861_4150001_Assignment#page7.tif
source=1861_4150001_Assignment#page8.tif
source=1861_4150001_Assignment#page9.tif
source=1861_4150001_Assignment#page10.tif
source=1861_4150001_Assignment#page11.tif
source=1861_4150001_Assignment#page12.tif
source=1861_4150001_Assignment#page13.tif
source=1861_4150001_Assignment#page14.tif
source=1861_4150001_Assignment#page15.tif

ASSIGNMENT

In consideration of good and valuable consideration paid to each of the undersigned inventors: **John WATKINS, Alexander OKSCHE, Kevin SMITH, Heikki MANSIKKA, and Paul BAILEY**, hereby sell and assign to **EURO-CELTIQUE S.A.**, a corporation formed under the laws of Luxembourg, whose mailing address is 1, rue Jean Piret, L-2350 Luxembourg (formerly Boulevard de la Petrusse 122, L-2350 Luxembourg and then 2, Avenue Charles de Gaulle, L-1653 Luxembourg) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **DIHYDROETORPHINE FOR THE PROVISION OF PAIN RELIEF AND ANAESTHESIA** for which application(s) for patent in the United States of America has a § 371(c) date of November 30, 2015 (also known as United States Application No. 14/894,775, which is the U.S. national phase of International Application No. PCT/GB2014/000206, having an International Filing Date of May 30, 2014, and claiming priority to GB 1309654.0, filed on May 30, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: X 22nd Feb 2018 Signature of Inventor: X [Signature]
John WATKINS

Date: _____ Signature of Inventor: _____
Alexander OKSCHE

Date: _____ Signature of Inventor: _____
Kevin SMITH

Date: _____ Signature of Inventor: _____
Heikki MANSIKKA

Date: _____ Signature of Inventor: _____
Paul BAILEY

WITNESS

☒ K.P. Shields.
(signature)

☒ KAREN SHIELDS ☒ MRS.
(name) (title)

☒ FOLKSWORTH 22ND FEBRUARY 2018
(place/date of signature)

☒ 37 TOWNSEND WAY PETERBOROUGH PET 3TU.
(address)

WITNESS

☒ [Signature]
(signature)

☒ JOSEPH SHIELDS ☒ OR
(name) (title)

☒ FOLKSWORTH 22/02/2018
(place/date of signature)

☒ 37 TOWNSEND WAY, FOLKSWORTH, PETERBOROUGH, PET 3TU
(address)

8333179_1

ASSIGNMENT

In consideration of good and valuable consideration paid to each of the undersigned inventors: **John WATKINS, Alexander OKSCHE, Kevin SMITH, Heikki MANSIKKA, and Paul BAILEY**, hereby sell and assign to **EURO-CELTIQUE S.A.**, a corporation formed under the laws of Luxembourg, whose mailing address is 1, rue Jean Piret, L-2350 Luxembourg (formerly Boulevard de la Petrusse 122, L-2350 Luxembourg and then 2, Avenue Charles de Gaulle, L-1653 Luxembourg) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **DIHYDROETORPHINE FOR THE PROVISION OF PAIN RELIEF AND ANAESTHESIA** for which application(s) for patent in the United States of America has a § 371(c) date of November 30, 2015 (also known as United States Application No. 14/894,775, which is the U.S. national phase of International Application No. PCT/GB2014/000206, having an International Filing Date of May 30, 2014, and claiming priority to GB 1309654.0, filed on May 30, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.


The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
John WATKINS

Date: 20/10/2017 Signature of Inventor: 
Alexander OKSCHE

Date: _____ Signature of Inventor: _____
Kevin SMITH

Date: _____ Signature of Inventor: _____
Heikki MANSIKKA

Date: _____ Signature of Inventor: _____
Paul BAILEY

WITNESS

Stefan Müller
(signature)

Stefan Müller Senior Scientific Manager
(name) (title)

Limburg 20.10.2017
(place/date of signature)

Mundipharma Research GmbH & Co. KG, 65549 Limburg, Germany
(address)

WITNESS

Anja Schneider
(signature)

Anja Schneider Management-Assistent
(name) (title)

Limburg 20th Oct 2017
(place/date of signature)

Mundipharma Research GmbH & Co. KG, 65548 Limburg
(address) Germany

8333179_1

ASSIGNMENT

In consideration of good and valuable consideration paid to each of the undersigned inventors: **John WATKINS, Alexander OKSCHE, Kevin SMITH, Heikki MANSIKKA, and Paul BAILEY**, hereby sell and assign to **EURO-CELTIQUE S.A.**, a corporation formed under the laws of Luxembourg, whose mailing address is 1, rue Jean Piret, L-2350 Luxembourg (formerly Boulevard de la Petrusse 122, L-2350 Luxembourg and then 2, Avenue Charles de Gaulle, L-1653 Luxembourg) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **DIHYDROETORPHINE FOR THE PROVISION OF PAIN RELIEF AND ANAESTHESIA** for which application(s) for patent in the United States of America has a § 371(c) date of November 30, 2015 (also known as United States Application No. 14/894,775, which is the U.S. national phase of International Application No. PCT/GB2014/000206, having an International Filing Date of May 30, 2014, and claiming priority to GB 1309654.0, filed on May 30, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
John WATKINS

Date: _____ Signature of Inventor: _____
Alexander OKSCHE

Date: 17th October, 2017 Signature of Inventor: [Signature]
Kevin SMITH

Date: _____ Signature of Inventor: _____
Heikki MANSIKKA

Date: _____ Signature of Inventor: _____
Paul BAILEY

WITNESS

Helen O'Conor
(signature)

Helen O'Conor Senior Clinical Pharmacokineticist
(name) (title)

Cambridge 17th October 2017
(place/date of signature)

Mundipharma Research, Cambridge Science Park, CB4 0AB
(address)

WITNESS

Gill Mondin
(signature)

GILL MONDIN PHARMACOKINETICS MANAGER
(name) (title)

CAMBRIDGE, 17th OCTOBER 2017
(place/date of signature)

MUNDIPHARMA RESEARCH LTD, CAMBRIDGE SCIENCE PARK, CB4 0AB
(address)

8333179_1

ASSIGNMENT

In consideration of good and valuable consideration paid to each of the undersigned inventors: **John WATKINS, Alexander OKSCHE, Kevin SMITH, Heikki MANSIKKA, and Paul BAILEY**, hereby sell and assign to **EURO-CELTIQUE S.A.**, a corporation formed under the laws of Luxembourg, whose mailing address is 1, rue Jean Piret, L-2350 Luxembourg (formerly Boulevard de la Petrusse 122, L-2350 Luxembourg and then 2, Avenue Charles de Gaulle, L-1653 Luxembourg) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **DIHYDROETORPHINE FOR THE PROVISION OF PAIN RELIEF AND ANAESTHESIA** for which application(s) for patent in the United States of America has a § 371(c) date of November 30, 2015 (also known as United States Application No. 14/894,775, which is the U.S. national phase of International Application No. PCT/GB2014/000206, having an International Filing Date of May 30, 2014, and claiming priority to GB 1309654.0, filed on May 30, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
John WATKINS

Date: _____ Signature of Inventor: _____
Alexander OKSCHE


Date: _____ Signature of Inventor: _____
Kevin SMITH

corrected / H.M.

Appl. No. 14/894,775

Atty. Docket No. 1861.4150001/JMC/THN

Date: Nov 2, 2017

Signature of Inventor: 

Heikki MANSIKKA

Date: _____

Signature of Inventor: _____

Paul BAILEY

WITNESS



(signature)

Joseph Sulowski
(name)

Clinical Operations Manager
(title)

Chromocell 02 Nov 2017
(place/date of signature)

3 Dogwood Lane, Phillipsburg, NJ 08865
(address)

WITNESS



(signature)

CHRISTOPHER FRANCINI
(name)

RESEARCH SCIENTIST
(title)

CHROMOCELL 02 NOV 2017
(place/date of signature)

17 MARKHAM RD, EDISON, 08817
(address)

8333179_1

ASSIGNMENT

In consideration of good and valuable consideration paid to each of the undersigned inventors: **John WATKINS, Alexander OKSCHE, Kevin SMITH, Heikki MANSIKKA, and Paul BAILEY**, hereby sell and assign to **EURO-CELTIQUE S.A.**, a corporation formed under the laws of Luxembourg, whose mailing address is 1, rue Jean Piret, L-2350 Luxembourg (formerly Boulevard de la Petrusse 122, L-2350 Luxembourg and then 2, Avenue Charles de Gaulle, L-1653 Luxembourg) (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **DIHYDROETORPHINE FOR THE PROVISION OF PAIN RELIEF AND ANAESTHESIA** for which application(s) for patent in the United States of America has a § 371(c) date of November 30, 2015 (also known as United States Application No. 14/894,775, which is the U.S. national phase of International Application No. PCT/GB2014/000206, having an International Filing Date of May 30, 2014, and claiming priority to GB 1309654.0, filed on May 30, 2013), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
John WATKINS

Date: _____ Signature of Inventor: _____
Alexander OKSCHE

Date: _____ Signature of Inventor: _____
Kevin SMITH

Date: _____ Signature of Inventor: _____
Heikki MANSIKKA

Date: 11 May '18 Signature of Inventor: Paul Bailey
Paul BAILEY

WITNESS

CS
(signature)

COLIN ROGERS MR
(name) (title)

CAMBRIDGE 11/5/18
(place/date of signature)

10 LOVELL RD CAMBRIDGE CB4 2QR
(address)

WITNESS

John Rogers
(signature)

MARGARET ROGERS (MRS)
(name) (title)

CAMBRIDGE 11/5/18
(place/date of signature)

10 LOVELL RD CAMBRIDGE CB4 2QR
(address)

8333179_1